¿Qué servicio? Contacto Solicitud

NCT06634875

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

← Centro de ensayos clínicos

Campos del registro

Estado general: RECRUITING
Condiciones: Colorectal Cancer Metastatic
Tipo de estudio: INTERVENTIONAL
Fase: PHASE2
Objetivo principal: TREATMENT
Tipo de intervención: DRUG
Intervenciones: isunakinra
Patrocinador principal: Buzzard Pharmaceuticals (INDUSTRY)

En caché: 2026-10-24 01:14:35

Ver en ClinicalTrials.gov

Resumen breve

This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.

Contacto

¿Necesita un informe o redacción médica basada en este ensayo?

Solicitar un informe Redacción médica Informe de investigación a medida

Atención al cliente